Online inquiry

IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2075MR)

This product GTTS-WQ2075MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL17A gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002190.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605
UniProt ID Q16552
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2075MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ15072MR IVTScrip™ mRNA-Anti-KDR, SSS-23(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SSS-23
GTTS-WQ9972MR IVTScrip™ mRNA-Anti-env, KD-247(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA KD-247
GTTS-WQ1431MR IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ACC-001
GTTS-WQ15750MR IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA VX-15
GTTS-WQ15370MR IVTScrip™ mRNA-Anti-ENG, TRC-105(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA TRC-105
GTTS-WQ5516MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CDP4940
GTTS-WQ15874MR IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA XmAb5871
GTTS-WQ1721MR IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ADC-1013
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW